Search results for "DOT"

showing 10 items of 5147 documents

AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A″-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild …

2021

Abstract Background Combining the advantages of both cyclic and acyclic chelator systems, AAZTA (1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-methylperhydro-1,4-diazepine) is well suited for complexation of various diagnostic and therapeutic radiometals such as gallium-68, scandium-44 and lutetium-177 under mild conditions. Due to its specificity for primary amines and pH dependent binding properties, squaric acid (SA) represents an excellent tool for selective coupling of the appropriate chelator to different target vectors. Therefore, the aim of this study was to evaluate radiolabeling properties of the novel bifunctional AAZTA5-SA being coupled to a model antibody (bevacizumab) i…

Cancer Researchmedicine.drug_classRadiochemistryKineticsSize-exclusion chromatographySquaramideSquaric acidMonoclonal antibody030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesismedicineMolecular MedicineDOTARadiology Nuclear Medicine and imagingChelationBifunctionalNuclear Medicine and Biology
researchProduct

Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide.

2003

There is increasing evidence for biological functions of human C-peptide. Recently, we have described that proinsulin C-peptide increases nutritive capillary blood flow and restores erythrocyte deformability in type 1 diabetic patients, whereas it has no such effect in non-diabetic subjects. The aim of the current study was to elucidate cellular mechanisms of this vasodilator effect in vitro by measuring the nitric oxide (NO)-mediated increase of cGMP production in a RFL-6 reporter cell assay and by demonstrating endothelial calcium influx with the Fluo-3 technique. C-peptide increased the release of NO from endothelial NO synthase (eNOS) in bovine aortic endothelial cells in a concentratio…

Cancer Researchmedicine.medical_specialtyArginineNitric Oxide Synthase Type IIIPhysiologyClinical BiochemistryBlotting WesternStimulationVasodilationBiologyNitric OxideBiochemistryNitroarginineNitric oxidechemistry.chemical_compoundEnosInternal medicinemedicineErythrocyte deformabilityAnimalsHumansEnzyme InhibitorsCyclic GMPProinsulinFluorescent DyesAniline CompoundsC-PeptideC-peptideReverse Transcriptase Polymerase Chain ReactionEndothelial Cellsbiology.organism_classificationEndocrinologychemistryMicroscopy FluorescenceXanthenesRNACalciumCattleNitric Oxide SynthaseNitric oxide : biology and chemistry
researchProduct

Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.

2010

Bisphosphonate associated osteonecrosis of the jaw (BP-ONJ) is one of the main side effects of bisphosphonate therapy (BPT). To date, there is no effective therapy of the BP-ONJ. Nitrogen-containing bisphosphonates (N-BPs) are particularly able to inhibit pyrophosphate synthase (FPPS) in the mevalonate pathway (MVP). Consequent of decreased synthesis of the metabolite Geranylgeraniol (GGOH) is believed to largely account for the development of BP-ONJ. Negative effect of N-BPs could be shown, resulting in decreased viability and migration capacity of different cell types of hard and soft tissues such as osteoblasts, fibroblast und endothelial cells. Aim of our in vitro study was to demonstra…

Cancer Researchmedicine.medical_specialtyCell typeCellIn Vitro Techniqueschemistry.chemical_compoundGeranylgeraniolmedicineHumansFibroblastBisphosphonate-associated osteonecrosis of the jawMigration AssayOsteoblastsBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisEndothelial CellsFibroblastsmedicine.diseaseSurgerymedicine.anatomical_structureOncologychemistryCancer researchMevalonate pathwayOral SurgeryDiterpenesbusinessWound healingJaw DiseasesOral oncology
researchProduct

Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene.

2003

Cushing's syndrome and systemic administration of glucocorticoids are associated with hypertension, but the underlying molecular mechanism is only partially understood. We have shown previously that dexamethasone downregulates the expression of the endothelial NO synthase (eNOS) gene in human endothelial cells and in the rat and that this may contribute to the blood pressure-raising effect of the steroid [Proc. Natl. Acad. Sci. USA 96 (1999) 13357]. In the current communication, we demonstrated that dexamethasone increased mean arterial blood pressure in wild-type C-57 Bl6 mice (eNOS+/+ mice), but had no effect on blood pressure in mice with a disrupted eNOS gene (eNOS-/- mice) derived from…

Cancer Researchmedicine.medical_specialtyEndotheliumNitric Oxide Synthase Type IIIPhysiologyClinical BiochemistryNitric Oxide Synthase Type IIBlood PressureBiologyKidneyNitric OxideBiochemistryDexamethasoneMiceDownregulation and upregulationEnosInternal medicinemedicineAnimalsEnzyme InhibitorsDexamethasoneMice KnockoutKidneyMyocardiumNitric Oxide Synthase Type IIIbiology.organism_classificationmedicine.anatomical_structureBlood pressureEndocrinologyLiverPharmacogeneticsHypertensionSystemic administrationNitric Oxide Synthasemedicine.drugNitric oxide : biology and chemistry
researchProduct

Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines

2008

Adaptation to hypoxia, a universal hallmark of carcinomas, is a critical step for tumor cell survival and growth. One of the principal regulators of hypoxia-responsive pathways is the transcription factor hypoxia-inducible factor-1 alpha (HIF-1 alpha). Currently, it is known that tumoral production of members of the vascular endothelial growth factor (VEGF)-family (VEGFs) may promote tumor growth and progression by acting on carcinoma cells that express the cognate receptors (VEGFRs). However, the influence of hypoxia in the formation of such a tumoral VEGF/VEGFR loop is not completely understood. In the present study we examined the potential existence of a HIF-1 alpha/VEGF/VEGFR autocrine…

Cancer Researchmedicine.medical_specialtyLung NeoplasmsVascular Endothelial Growth Factor CCellBreast NeoplasmsBiologychemistry.chemical_compoundDownregulation and upregulationCell Line TumorInternal medicinemedicineHumansAutocrine signallingVascular Endothelial Growth Factor Receptor-1CarcinomaKinase insert domain receptorCell cycleHypoxia-Inducible Factor 1 alpha SubunitVascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2Cell HypoxiaUp-RegulationGene Expression Regulation NeoplasticVascular endothelial growth factorAutocrine CommunicationHIF1AEndocrinologymedicine.anatomical_structureOncologyVascular endothelial growth factor CchemistryCancer researchColorectal NeoplasmsInternational Journal of Oncology
researchProduct

Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs.

2002

In many types of cardiovascular pathophysiology such as hypercholesterolemia and atherosclerosis, diabetes, cigarette smoking, or hypertension (with its sequelae stroke and heart failure) the expression of endothelial NO synthase (eNOS) is altered. Both up- and downregulation of eNOS have been observed, depending on the underlying disease. When eNOS is upregulated, the upregulation is often futile and goes along with a reduction in bioactive NO. This is due to an increased production of superoxide generated by NAD(P)H oxidase and by an uncoupled eNOS. A number of drugs with favorable effects on cardiovascular disease upregulate eNOS expression. The resulting increase in vascular NO producti…

Cancer Researchmedicine.medical_specialtyNitric Oxide Synthase Type IIIPhysiologyClinical BiochemistryPharmacologymedicine.disease_causeNitric OxideBiochemistrychemistry.chemical_compoundDownregulation and upregulationMetabolic DiseasesEnosInternal medicineDiabetes mellitusmedicineAnimalsHumansEndothelial dysfunctionAngiotensin II receptor type 1biologybusiness.industrySuperoxidemedicine.diseasebiology.organism_classificationEndocrinologychemistryGene Expression RegulationErythropoietinCardiovascular DiseasesNitric Oxide SynthasebusinessOxidative stressmedicine.drugNitric oxide : biology and chemistry
researchProduct

Physiological mechanisms regulating the expression of endothelial-type NO synthase

2002

Although endothelial nitric oxide synthase (eNOS) is a constitutively expressed enzyme, its expression is regulated by a number of biophysical, biochemical, and hormonal stimuli, both under physiological conditions and in pathology. This review summarizes the recent findings in this field. Shear stress, growth factors (such as transforming growth factor-beta, fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth factor), hormones (such as estrogens, insulin, angiotensin II, and endothelin 1), and other compounds (such as lysophosphatidylcholine) upregulate eNOS expression. On the other hand, the cytokine tumor necrosis factor-alpha and bacterial lipopolys…

Cancer Researchmedicine.medical_specialtyNitric Oxide Synthase Type IIIPhysiologyRNA Stabilitymedicine.medical_treatmentClinical BiochemistryBiologyFibroblast growth factorBiochemistryGene Expression Regulation Enzymologicchemistry.chemical_compoundEnosInternal medicinemedicineAnimalsPromoter Regions GeneticRegulation of gene expressionBase SequenceGene Expression ProfilingGrowth factorbiology.organism_classificationActin cytoskeletonAngiotensin IICell biologyVascular endothelial growth factorEndocrinologychemistryNitric Oxide SynthaseSignal transductionSignal TransductionNitric Oxide
researchProduct

Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.

2019

e22540 Background: Epithelioid hemangioendothelioma (EHE) is an exceedingly rare soft tissue sarcoma subtype. EHE often presents as a multifocal/ multivisceral disease and its clinical behavior is highly unpredictable from indolent to very aggressive forms. A common choice in advanced patients is a close, active surveillance (AS), considering a treatment only in case of disease progression. Our retrospective study aimed to identify clinical features associated with a more aggressive behavior. Methods: Patients affected by advanced EHE treated in 6 centers of the Italian Rare Cancer Network were retrospectively reviewed. Diagnosis was confirmed by a sarcoma expert pathologist and molecular …

Cancer Researchmedicine.medical_specialtyOncologyPleural effusionbusiness.industrySoft tissue sarcomamedicineRadiologymedicine.diseasebusinessEpithelioid hemangioendotheliomaJournal of Clinical Oncology
researchProduct

Cellular mechanism of action of thyroid hormones.

1987

Abstract It has emerged in the last decade that the molecular mechanism of action of thyroid hormones resembles that of steroids; thyroid hormones indeed exert their effects mainly by directly regulating gene expression, on association with specific chromatin-bound receptors. Of the two thyroid hormones, thyroxine (T4) appears to be a sort of prohormone, whereas triiodothyronine (T3) seems to be the active form; in this respect, T4-deiodination, which occurs at the level of the target tissues, may be crucial in the local homeostasis of T3. Moreover, many cellular compartments, other than the nucleus, can bind thyroid hormone, and at least some of these further sites might play some role in …

Cancer Researchmedicine.medical_specialtyThyroid HormonesTriiodothyronineReceptors Thyroid HormoneProhormoneThyroidCell BiologyBiologyChromatinEndocrinologymedicine.anatomical_structureMechanism of actionGene Expression RegulationInternal medicinemedicineAnimalsmedicine.symptomReceptorMolecular BiologyCellular compartmentDevelopmental Biologymedicine.drugHormoneDifferentiation; research in biological diversity
researchProduct

Association between Pterostilbene and Quercetin Inhibits Metastatic Activity of B16 Melanoma

2005

AbstractInhibition of cancer growth by resveratrol (trans-3,5,4'trihydroxystilbene; RESV), a phytoalexin present in many plant species, is limited by its low bioavailability. Pterostilbene (3,5-dimethoxy-4'-hydroxystilbene; PTER) and quercetin (3,3',4',5,6-pentahydroxyflavone; QUER), two structurally related and naturally occurring small polyphenols, show longer half-life in vivo. In vitro growth of highly malignant B16 melanoma F10 cells (B16M-F10) is inhibited (56%) by short-time exposure (60 min/day) to PTER (40 μM) and QUER (20 μM) (approximate mean values of plasma concentrations measured within the first hour after intravenous administration of 20 mg/kg of each polyphenol). Intravenou…

Cancer ResearchpterostilbenePterostilbeneEndotheliumMelanomaPolyphenolsResveratrolPharmacologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282quercetinchemistry.chemical_compoundmedicine.anatomical_structurechemistryBiochemistryIn vivomedicinemelanomaVCAM-1Cell adhesionQuercetinmetastasesNeoplasia: An International Journal for Oncology Research
researchProduct